Investor's Business Daily
Dow Jones Futures Fall After Christmas; Nvidia's Big AI Deal
📈
AI Sentiment
Highly Positive
10/10
- Home
- TVTX
as of 12-29-2025 3:39pm EST
$38.55
$1.09
-2.74%
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.3B | IPO Year: | N/A |
| Target Price: | $37.21 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.91 - $42.13 | Next Earning Date: | 10-30-2025 |
| Revenue: | $435,826,000 | Revenue Growth: | 114.22% |
| Revenue Growth (this year): | 120.02% | Revenue Growth (next year): | 37.00% |
AI-Powered TVTX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 69.28%
69.28%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
Calvin Sandra
Sell
SVP, CHIEF ACCOUNTING OFFICER
TVTX Dec 15, 2025
Avg Cost/Share
$36.00
Shares
2,910
Total Value
$104,760.00
Owned After
45,635
SEC Form 4
Cline Christopher R.
Sell
CHIEF FINANCIAL OFFICER
TVTX Dec 1, 2025
Avg Cost/Share
$35.01
Shares
20,000
Total Value
$700,202.00
Owned After
92,083
SEC Form 4
Calvin Sandra
Sell
SVP, CHIEF ACCOUNTING OFFICER
TVTX Nov 4, 2025
Avg Cost/Share
$36.00
Shares
67,115
Total Value
$2,416,140.00
Owned After
45,635
SEC Form 4
Heerma Peter
Sell
CHIEF COMMERCIAL OFFICER
TVTX Oct 31, 2025
Avg Cost/Share
$35.00
Shares
5,591
Total Value
$195,685.00
Owned After
119,071
SEC Form 4
COUGHLIN TIMOTHY
Sell
Director
TVTX Oct 31, 2025
Avg Cost/Share
$35.03
Shares
18,000
Total Value
$630,601.20
Owned After
55,500
SEC Form 4
Dube Eric M
Sell
CHIEF EXECUTIVE OFFICER
TVTX Oct 29, 2025
Avg Cost/Share
$30.12
Shares
27,128
Total Value
$817,073.66
Owned After
419,173
SEC Form 4
Dube Eric M
Sell
CHIEF EXECUTIVE OFFICER
TVTX Oct 28, 2025
Avg Cost/Share
$30.38
Shares
92,872
Total Value
$2,821,358.49
Owned After
419,173
SEC Form 4
Heerma Peter
Sell
CHIEF COMMERCIAL OFFICER
TVTX Oct 28, 2025
Avg Cost/Share
$30.00
Shares
2,662
Total Value
$79,860.00
Owned After
119,071
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Dec 15, 2025 | Sell | $36.00 | 2,910 | $104,760.00 | 45,635 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Dec 1, 2025 | Sell | $35.01 | 20,000 | $700,202.00 | 92,083 | |
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Nov 4, 2025 | Sell | $36.00 | 67,115 | $2,416,140.00 | 45,635 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Oct 31, 2025 | Sell | $35.00 | 5,591 | $195,685.00 | 119,071 | |
| COUGHLIN TIMOTHY | TVTX | Director | Oct 31, 2025 | Sell | $35.03 | 18,000 | $630,601.20 | 55,500 | |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Oct 29, 2025 | Sell | $30.12 | 27,128 | $817,073.66 | 419,173 | |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Oct 28, 2025 | Sell | $30.38 | 92,872 | $2,821,358.49 | 419,173 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Oct 28, 2025 | Sell | $30.00 | 2,662 | $79,860.00 | 119,071 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
Is Travere Therapeutics Still Attractively Priced After Its 135% Share Price Surge?
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Why Travere Therapeutics (TVTX) Is Up 18.9% After FDA Eases FILSPARI Oversight And Delays Adcom
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Travere Therapeutics (TVTX): Valuation Check After FDA Tailwinds and FSGS Expansion Hopes for FILSPARI
📈
AI Sentiment
Highly Positive
9/10
Motley Fool
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday
📈
AI Sentiment
Highly Positive
9/10
Compare TVTX vs Leading Stocks
See how TVTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.